CSE

AIML

OTCQB

AIMLF

FWB

42FB

PRESS RELEASE

August 21, 2025

AIML Announces SEDAR Filing

Vancouver, Canada – August 21, 2025 – AI/ML Innovations Inc. (“AIML” or the “Company”) (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) is issuing the following press release to clarify its disclosure as a result of a review by the British Columbia Securities Commission. The Company announces today that it has filed an amended and restated management's discussion and analysis for the three and nine month periods ended January 31, 2025 (the "Amended MD&A") in order to rectify certain disclosure deficiencies, including:

● to provide enhanced disclosure relating to (i) new strategic initiatives and R&D activities of the Company; (ii) the results of operations of the Company for the three and nine month periods ended January 31, 2025; and (iii) the acquisitions by the Company of Quantum Sciences Ltd. and certain other intangible assets and associated intellectual property during the period;

● to incorporate additional details regarding payments made to related parties during the period;

● to include a discussion of the exit agreement with Tech2Heal; and

● to incorporate other minor housekeeping changes.

The Amended MD&A is available on SEDAR+ at www.sedarplus.ca.

For more information about AIML:

For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.

Contact:
Blake Fallis
(778) 405-0882
info@aiml.health

About AIML Innovations Inc.
https://www.aiml.health/

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights - supporting earlier diagnosis, personalized treatment, and more effective care. AIML’s shares trade on the Canadian Securities Exchange (CSE: AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

On behalf of the Board of Directors:
Paul Duffy, Chairman

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements – Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Such statements remain subject to various risks, including risks relating to the proposed future operations of the Company, availability of funding, industry developments and competition. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company disclaims any obligation to update such forward looking statements other than as required by law.

More press releases

Recent announcements from AI/ML Innovations.

September 29, 2026

AIML Subsidiary NeuralCloud Enters Strategic Partnership with RKS Medical Technologies to Advance CardioYield™ Clinical Pilots

September 21, 2026

AI/ML Innovations Launches Quantum Soma Initiative with Dynex Quantum Technologies for Contactless Quantum Biosensing Platform

September 1, 2026

AI/ML Innovations subsidiary NeuralCloud Appoints Former FDA Reviewer Dr. Mehmet Kosoglu as the Head of Regulatory Affairs

August 26, 2026

AI/ML Innovations Inc. Closes First Tranche of Private Placement

August 18, 2026

AIML Subsidiary NeuralCloud Signs Term Sheet with Island Mobile Cardiology Testing for CardioYield™ Pilot

August 14, 2026

AI/ML Innovations Inc. Announces Proposed Private Placement

August 11, 2026

AI/ML Innovations’ Subsidiary NeuralCloud Achieves ISO 13485:2016 (MDSAP) Certification